Moneycontrol
Get App
SENSEX NIFTY
you are here:

Glenmark Pharma Ltd.

BSE: 532296 | NSE: GLENMARK |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE935A01035 | SECTOR: Pharmaceuticals

Success
Alert
Please select a Day.
Info

BSE Live

Feb 20, 16:00
321.35 3.45 (1.09%)
Volume
AVERAGE VOLUME
5-Day
149,233
10-Day
102,377
30-Day
79,444
60,031
  • Prev. Close

    317.90

  • Open Price

    319.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Feb 20, 15:57
321.55 3.45 (1.08%)
Volume
AVERAGE VOLUME
5-Day
3,254,420
10-Day
2,254,446
30-Day
1,994,637
1,529,171
  • Prev. Close

    318.10

  • Open Price

    318.10

  • Bid Price (Qty.)

    321.55 (664)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Glenmark

  • Feb 14, 2020 19:06 Source: BSE

    Glenmark Pharma - Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2019

    The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on February 14, 2020, which commenced at 02.00 p.m. and concluded at 6.40 p.m., considered and approved the following: 1. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.

  • Feb 11, 2020 17:32 Source: BSE

    Glenmark Pharma - Update on board meeting

    The Board Meeting to be held on 14/02/2020 has been revised to 14/02/2020 We have to inform you that the Board of Directors of the Company, at its meeting scheduled on February 14, 2020, will, inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, of any of the above, for refinancing of bonds/FCCBs/loans, in accordance with the FEMA ECB Guidelines, and other applicable regulations, guidelines and laws of India, and subject to all necessary regulatory, statutory and shareholder approvals, as may be required.

  • Feb 04, 2020 12:57 Source: NSE

    Glenmark Pharmaceuticals Limited

    Glenmark Pharmaceuticals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates slated for Monday, February 17, 2020 at 8:30 a.m. 9:30 a.m. (IST)

  • Feb 04, 2020 12:31 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Enclosed please find herewith the details of Earnings Call slated for Monday, February 17, 2020 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.

  • Jan 31, 2020 18:24 Source: BSE

    Glenmark Pharma - Closure of Trading Window

    We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2019 to February 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019.

  • Jan 31, 2020 18:20 Source: BSE

    Glenmark Pharma - Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2019.

    GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, February 14, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2019. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2019 to February 16, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2019.

  • Jan 21, 2020 18:02 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Meeting Updates

    Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Jan 14, 2020 8:38 Source: NSE

    Glenmark Pharmaceuticals Limited

    Glenmark Pharmaceuticals Limited has informed the Exchange regarding ''Re: Intimation under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR") ''.

  • Jan 14, 2020 7:09 Source: BSE

    Glenmark Pharma - Re: Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")

    This is in furtherance to our letter dated May 29, 2019 whereby we had informed the stock exchanges that the Board of Directors of Glenmark Pharmaceuticals Limited (''Company'') at its meeting held on May 29, 2019 had approved issuance of bonds, whether denominated in Indian Rupee or foreign currency, for an aggregate amount not exceeding USD 200 million in the international market as per applicable law. Further to the above, we hereby inform you that the Company is contemplating issuance of USD denominated notes for an aggregate amount not exceeding USD 200 million (''Notes'') subject to market conditions, and the Company''s officials will be participating in roadshow presentations from January 14, 2020 to January 19, 2020 covering Asia, Europe and Middle East.

  • Jan 10, 2020 13:49 Source: BSE

    Glenmark Pharma - Statement Of Investor Complaints For The Quarter Ended December 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0220
    Name of the Signatory :- Harish Kuber
    Designation :- Company Secretary and Compliance Officer

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Feb 14, 2020
Remark : Quarterly Results & Others